But I think across both pemphigus and pemphigoid, we're starting to see more nonbullous presentations, specifically in pemphigoid. How has the emergence of new therapies changed your approach to managing patients with bullous diseases? For pemphigus, the first-line treatment that most people are doing is rituximab, especially for moderate to severe disease. For pemphigoid, we used to have only really toxic treatments to offer our elderly patients with pemphigoid. Now, with FDA approval of dupilumab, we have something that's safer, and it really does change the risk-benefit ratio of starting a systemic medication and one that's really targeted to the pathophysiology of the disease.